LEXINGTON, Mass., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the
development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that the
Company will present at the Baird 2017 Global Healthcare Conference on September 6 at 10:15 a.m. EDT in New York.
The presentation will be held using a fireside-chat format in which Ali Fattaey, Ph.D. President and Chief Executive Officer,
will provide a brief overview of the Company's pipeline of drug candidates and business strategy, after which an equity analyst
will moderate a question and answer session.
A corresponding webcast of the presentation can be accessed by visiting:
http://wsw.com/webcast/baird49/register.aspx?conf=baird49&page=cris
The webcast will be archived shortly after the live event and available for 30 days following the conference, and also available
for 30 days on the Investor Relations section of the Curis website at www.curis.com.
About Curis
Curis is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates
for the treatment of human cancers, including its lead development candidate, CUDC-907, which is being investigated in clinical
studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of
immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule
antagonists of the PD1 and VISTA pathways, including PDL1/VISTA antagonist CA-170, and oral small molecule antagonists of the PD1
and TIM3 pathways, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including
CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas. Curis
is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing
Erivedge® for the treatment of advanced basal cell carcinoma, and are further developing Erivedge in myelofibrosis. For more
information, visit Curis's website at www.curis.com.
For More Information: James E. Dentzer Chief Financial Officer & Chief Administrative Officer Curis, Inc. 617-503-6500 jdentzer@curis.com Media Contact David Schull Russo Partners (212) 845-4271 david.schull@russopartnersllc.com
